Uromodulin as a Biomarker in Lupus Nephritis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
Evaluation of Uromodulin as a biomarker of renal histological activity/ Chronicity indices in lupus nephritis
Eligibility criteria
This trial accepts healthy volunteersQualifiers
• Group I: 30 patients with different classes of Lupus Nephritis. These cases are biopsy proven
Biopsy-proven lupus nephritis at the time of uromodulin blood sampling.
Group II: 10 patients with active SLE without renal involvement and with SLEDAI score ≥6
Group III: 10 patients with non-active SLE with SLEDAI score <6
Disqualifiers
• .Pregnancy or lactation
AKI secondary to pre renal OR post renal cause (from clinical history and imaging).
End-stage renal disease requiring dialysis
Active infection or sepsis
Trial population
Nephrology and Rheumatology unit, Assiut University Hospital
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
To determine the correlation between serum uromodulin levels and renal histopathological Activity Index (AI) and Chronicity Index (CI) in patients with biopsy-proven lupus nephritis.
Time frame
3yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: